AVEO Oncology announced the appointment of Edgar Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development. Braendle brings more than twenty years of clinical research experience to AVEO Oncology, most recently serving as Chief Development Officer of Autolus Therapeutics. AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee. This esteemed group of experts in oncology research and clinical development were selected to advise and bring unique perspectives to AVEO and LG Chem’s clinical strategy and business development initiatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics price target raised to $10 from $9 at Truist
- Autolus Therapeutics Announces Annual Results and CDO Resignation
- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
- Autolus Therapeutics says ‘well capitalized’ for pipeline development plans
- Autolus Therapeutics reports 2023 EPS ($1.20), consensus ($1.01)